Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech, Inc. (OTC: NKGN) is a clinical-stage biotechnology company headquartered in Santa Ana, California, focused on autologous and allogeneic natural killer (NK) cell therapeutics. The NKGN news feed highlights company announcements, scientific presentations, regulatory updates, and corporate developments that shape its NK cell therapy programs.
Readers can find detailed coverage of NKGen’s work on troculeucel, a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate and the International Nonproprietary Name (INN) for SNK01. News items include presentations on troculeucel’s mechanism of action and biomarker data in Alzheimer’s disease, as well as updates on its evaluation across multiple neurodegenerative diseases through clinical trials and an FDA Expanded Access Program authorization.
The news stream also features information on NKGen’s allogeneic NK cell therapy, SNK02, in solid tumors, including scientific and early clinical findings shared at immuno-oncology conferences. Corporate news covers NKGen’s acquisition of a majority equity stake in NKGen Biotech Korea Co., Ltd. (formerly NKMax Co., Ltd.), governance developments at NKGen Korea, and strategic partnerships such as its collaboration with HekaBio in Japan to advance troculeucel under Japan’s regenerative medicine framework.
In addition, NKGen issues updates on its trading status on the OTC Expert Market, clarifying quotation practices and reporting steps taken to address reporting obligations. Investors and observers can use the NKGN news page to follow how NKGen communicates progress in its NK cell therapy pipeline, regional collaborations, manufacturing and intellectual property consolidation, and interactions with regulators and capital providers.
NKGen Biotech presented updated Phase 1 data on its allogeneic NK cell therapy, SNK02, at the 6th Annual Allogeneic Cell Therapies Summit 2024. The therapy avoids lymphodepletion, aiming to preserve immune function and reduce toxicity. In the trial, 6 patients with advanced solid tumors received weekly intravenous doses of SNK02. Four patients completed 8 cycles, with stable disease observed in all. The treatment was generally well-tolerated, with most adverse events being mild. One death occurred but was deemed unrelated to the therapy. Further studies will explore SNK02 in combination with other immunotherapies.
NKGen Biotech (Nasdaq: NKGN) announced that CEO Paul Y. Song, MD, will present updated Phase 1 data on their SNK02 allogeneic NK cell therapy at the 6th Annual Allogeneic Cell Therapies Summit, June 10-12, 2024, in Boston, MA. The presentation, scheduled for June 12, will highlight the company's cryopreserved allogeneic NK cell therapy platform and the initial Phase 1 results for advanced refractory solid tumors. Dr. Song will discuss the potential benefits of eliminating pre-treatment lymphodepletion, which may reduce toxicity and preserve immune function. Further, the presentation will explore unexpected findings from the SNK02 trial that suggest its use beyond cancer treatment. A copy of the presentation will be available on the company's website post-event.
NKGen Biotech has announced interim results from its Phase 1 clinical trial of SNK02, an allogeneic NK cell therapy for advanced solid tumors, at the 2024 ASCO Annual Meeting.
The trial showed that SNK02 was well-tolerated and demonstrated a stable disease response in 100% of patients completing 8 treatment cycles. The study involved five patients with refractory solid tumors, averaging four prior lines of therapy, and a median age of 64.
SNK02 did not require lymphodepletion before administration and exhibited some clinical activity as a monotherapy. Adverse events were mostly mild with one Grade 3 event resolving without intervention.
The company plans to continue studying SNK02 in combination with monoclonal antibodies and immune checkpoint inhibitors.
NKGen Biotech announced that its cryopreserved, enhanced natural killer cell therapy, SNK01, has been cleared to progress into Phase 2 clinical trials for moderate Alzheimer’s disease. The therapy showed clinical benefit and no drug-related adverse events in Phase 1. The Phase 2 trial will involve 30 patients, with 20 receiving SNK01 and 10 receiving a placebo, and will begin in Q2 2024. This trial aims to assess the therapy's efficacy and safety over a full year. Preliminary results are promising, with improvements in cognitive function and daily activities observed.
NKGen Biotech, a clinical-stage biotech company, will present its autologous NK cell therapy, SNK01, at the 5th International Cell & Gene Therapy China Summit. SNK01, which shows enhanced cytotoxicity and receptor expression, targets neurodegenerative diseases and solid tumors. CEO Paul Y. Song will discuss manufacturing advances and results combining SNK01 with immune checkpoint inhibitors and Erbitux for resistant cancers. The presentation, set for May 23, 2024, will also highlight SNK01's potential against multiple neurodegenerative diseases by improving key protein levels.
NKGen Biotech, Inc. (NKGN) received FDA clearance for its SNK01 NK cell therapy in Parkinson's disease, advancing its neurodegenerative disease program. The Phase 1/2a clinical trial is set to commence in 2H 2024, with SNK01 showing promising potential in addressing Parkinson's disease through enhanced cytotoxicity and activating receptor expression.
Summary not available.
Summary not available.
Summary not available.
Summary not available.